Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit.
Transgene expression after the administration of recombinant adenovirus with E1 deleted is constantly transient. It is admitted that E1A-substituting activities of cellular or viral origin allow viral antigen synthesis and trigger cytotoxic lymphocyte-mediated clearance of the recipient cells. Our approach to solving this problem relies on the additional deletion of the E4 region from the vector backbone as this region upregulates viral gene expression at both transcriptional and posttranscriptional levels. As a prerequisite to the construction of E1 E4 doubly defective adenoviruses, we investigated the possibility of transcomplementing both functions within a single cell. In particular, the distal ORF6+ORF7 segment from the E4 locus of adenovirus type 5 was cloned under the control of the dexamethasone-inducible mouse mammary tumor virus long terminal repeat. Following transfection into 293 cells, clone IGRP2 was retained and characterized as it can rescue the growth defect of all E1+ E4- adenoviral deletants tested. DNA and RNA analysis experiments verified that the mouse mammary tumor virus promoter drives the expression of the ORF6+ORF7 unit and permits its bona fide alternative splicing, generating ORF6/7 mRNA in addition to the ORF6-expressing primary transcript. Importantly, IGRP2 cells sustain cell confluence for a period longer than that of 293 parental cells and allow the plaque purification of E1- or E4- defective viruses. The dual expression of E1 and E4 regulatory genes within IGRP2 cells is demonstrated by the construction, plaque purification, and helper-free propagation of recombinant lacZ-encoding doubly defective adenoviruses harboring different E4 deletions. In addition, the emergence, if any, of replicative particles during viral propagation in this novel packaging cell line will be drastically impaired as only a limited segment of E4 has been integrated.
Laboratoire des Virus Oncogènes, 1301/Rhône-Poulenc Rorer Gencell, Institut Gustave Roussy, Villejuif, France.
P
P
Yeh
J F
JF
Dedieu
C
C
Orsini
E
E
Vigne
P
P
Denefle
M
M
Perricaudet
D017498:Adenovirus E1 Proteins / Q000235:genetics*; D017504:Adenovirus E4 Proteins / Q000235:genetics*; D000260:Adenoviruses, Human / Q000235:genetics* / Q000254:growth & development; D000818:Animals; D001483:Base Sequence; D002213:Capsid / Q000378:metabolism; D036022:Capsid Proteins; D002460:Cell Line; D003001:Cloning, Molecular; D017353:Gene Deletion; D005814:Genes, Viral; D005816:Genetic Complementation Test; D006801:Humans; D007700:Kinetics; D008324:Mammary Tumor Virus, Mouse / Q000235:genetics; D008969:Molecular Sequence Data; D016366:Open Reading Frames; D011995:Recombination, Genetic; D012091:Repetitive Sequences, Nucleic Acid; D001616:beta-Galactosidase / Q000235:genetics / Q000378:metabolism
D017498:Adenovirus E1 Proteins; D017504:Adenovirus E4 Proteins; D036022:Capsid Proteins; C018315:hexon capsid protein, Adenovirus; D001616:beta-Galactosidase